Patents by Inventor Lyndi M. Rice

Lyndi M. Rice has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PME-1 as a biomarker to predict and diagnose endometrial and breast cancer and gene silencing of PME-1 to inhibit epithelial to mesenchymal transition
    Patent number: 9663789
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Grant
    Filed: October 15, 2014
    Date of Patent: May 30, 2017
    Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi M. Rice, Michelle Pusey
  • SiRNA TARGETING ETS1 AND ELK1 AND METHOD OF USING SAME IN THE INHIBITION OF CIP2A GENE IN CANCER TREATMENT
    Publication number: 20160082034
    Abstract: Disclosed are methods of attenuating activity of the gene promoter of CIP2A. siRNAs are used to target against Ets1 and Elk1 transcriptional factors, thereby blocking the binding of Ets1 and Elk1 to the CIP2A gene promoter. It is disclosed that the siRNAs targeted against Ets1 and Elk1 attenuate the gene expression of CIP2A. A kit containing siRNA reagents for attenuating the CIP2A gene expression is also disclosed.
    Type: Application
    Filed: August 20, 2015
    Publication date: March 24, 2016
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi M. Rice, Rajash Pallai
  • PME-1 AS A BIOMARKER TO PREDICT AND DIAGNOSE ENDOMETRIAL AND BREAST CANCER AND GENE SILENCING OF PME-1 TO INHIBIT EPITHELIAL TO MESENCHYMAL TRANSITION
    Publication number: 20150284723
    Abstract: Disclosed are methods of attenuating activity of the PME-1 gene. siRNAs or shRNAs are used to target against PME-1, thereby reducing the PME-1 mRNA. It is disclosed that the siRNAs or shRNAs targeted against PME-1 attenuate the epithelial to mesenchymal transition, thereby inhibit endometrial cancer and triple negative breast cancer development. A kit containing siRNA or shRNA reagents for attenuating the PME-1 gene expression is also disclosed.
    Type: Application
    Filed: October 15, 2014
    Publication date: October 8, 2015
    Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Lyndi M. Rice, Michelle Pusey
  • SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
    Patent number: 9139829
    Abstract: Disclosed are methods of attenuating activity of the gene promoter of CIP2A. siRNAs are used to target against Ets1 and Elk1 transcriptional factors, thereby blocking the binding of Ets1 and Elk1 to the CIP2A gene promoter. It is disclosed that the siRNAs targeted against Ets1 and Elk1 attenuate the gene expression of CIP2A. A kit containing siRNA reagents for attenuating the CIP2A gene expression is also disclosed.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: September 22, 2015
    Assignee: Medical Diagnostic Laboratories, LLC
    Inventors: Lyndi M. Rice, Rajash Pallai